Strategic Partner(s)

Alexander Hauser: GPCR Pharmacogenomics and Precision Psychiatry

GPCR drug targets carry genetic variation that is far more widespread across human populations than the field has historically appreciated. Hauser's research program asks a pointed question: if a patient fails to respond to a psychiatric drug, or experiences an adverse reaction, is there a GPCR variant in their genome that explains it - and can we find it systematically? To answer this, his work integrates GPCR molecular pharmacology with computational biology, population genetics, and pharmacoepidemiology, drawing on Denmark's iPSYCH biobank - a cohort of 100,000 genotyped psychiatric patients linked to national prescription registries. In parallel, his earlier work on orphan receptor deorphanization used co-evolution analysis and machine learning to generate candidate peptide ligands for putative peptide-binding orphan GPCRs, producing a library of 218 synthetic peptides and yielding the first confirmed hits. Together, these projects represent a rare attempt to connect the molecular detail of receptor pharmacology with the population-scale reality of how those receptors behave in living patients. For Hauser, the stakes are personal: precision psychiatry only matters if it eventually changes what a clinician prescribes.

About the Guest

Alexander Hauser is a postdoctoral researcher at the University of Copenhagen's Department of Drug Design and Pharmacology, with a part-time affiliation at the Institute for Biological Psychiatry. His research integrates GPCR molecular pharmacology, computational biology, and pharmacoepidemiology to study how human genetic variation in GPCR drug targets shapes drug response and disease risk at a population scale. He completed his PhD under David Gloriam in Copenhagen and an external stay at the MRC Laboratory of Molecular Biology in Cambridge with Madan Babu. His work spans structural analysis, machine learning, population genetics, and the clinical translation challenges that come with precision medicine.

Scientific Themes of the Conversation

The prevalence and functional consequences of GPCR genetic variants across human populations
Co-evolution and machine learning as a framework for orphan receptor deorphanization
Denmark's iPSYCH biobank as a unique resource for population-scale GPCR pharmacogenomics
The epistemological limits of computational pharmacology without domain knowledge
The translational gap between pharmacogenomics findings and clinical prescription practice
Interdisciplinary collaboration as a scientific strategy - and its structural requirements

Key Insights from the Conversation

1. GPCR variants are not rare edge cases - they are widespread and consequential

The prevailing assumption that human GPCR sequences are largely conserved does not hold at a population scale. Hauser's work identified that variants are continuously arising across GPCR drug targets and likely contribute to adverse drug reactions through several distinct mechanisms. This has direct implications for how drug safety is assessed and how clinical trials are designed.

2. Orphan receptors can be systematically approached through evolutionary logic

Rather than screening compound libraries blindly against orphan GPCRs, Hauser designed a ligand library by learning the structural and evolutionary logic of known peptide hormone - receptor pairings. The result was 218 candidate peptides, several of which produced confirmed hits in cell-based assays. The approach treats the evolutionary record as a pharmacological hypothesis generator.

3. Denmark's registry infrastructure makes a fundamentally different kind of science possible

Most biobanks require active consent and recruit selected populations that do not represent a country's full demographic range. Denmark's CPR number system links psychiatric diagnoses, prescription histories, genotypes, and demographic data across 100,000 patients - without recruitment bias. This allows Hauser to study GPCR variant effects in the context of real prescribing decisions, not controlled cohorts.

4. Computational skill without pharmacological domain knowledge produces noise, not insight

Hauser draws a sharp distinction between the ability to manipulate large datasets and the ability to interpret them. Knowing how a dataset was generated - what assay conditions, what cell lines, what confounders - is not optional context. It determines whether a computational finding is meaningful or meaningless. This is the argument for keeping computational pharmacologists embedded in pharmacological communities.

5. Translating pharmacogenomics to clinical practice requires clinical co-design from the start

Publishing a finding that GPCR variants predict drug response is not the same as changing a prescription. Hauser is direct about the gap: clinicians need to have shaped the question, not just received the answer. Research that bypasses clinical input tends to stay in the research community. The patient impact requires the clinician's voice in the design phase.

6. The breadth of a scientific career is sometimes a temperament, not a strategy

Hauser traces his integrative approach - bridging structural biology, evolutionary data, genetics, and psychiatry - back to a flexible undergraduate program and a deliberate resistance to early specialization. The same quality that led him to a working visa year in Australia before university is the quality that now lets him move across disciplinary boundaries without losing his footing in any of them.

Episode Timeline

Timestamps are AI-generated from the transcript and should be verified against the final edited audio before publication.

00:00 - Introduction and ecosystem announcements
01:33 - Hauser introduces himself - GPCRs, pharmacogenomics, and precision psychiatry
06:47 - Denmark's iPSYCH biobank and what makes nationwide registry data unique
09:15 - GDPR, unconsented patient data, and the ethics of population-scale research
10:14 - Origin story - hospital internship, Australia, and the decision to pursue science
13:06 - First exposure to computational chemistry - a rotation in Hyderabad
16:04 - Joining David Gloriam's group and first encounter with GPCRs
17:14 - What a computational GPCR scientist actually does across a typical week
20:51 - Having children during a PhD - why Denmark's culture makes it structurally possible
31:45 - Mentoring philosophy - teaching through mistakes and sustaining relationships after departure
37:19 - Networking, collaboration, and the danger of doing science in a bubble
44:18 - Building toward an independent group - precision psychiatry as the research anchor
46:06 - The translational challenge - convincing clinicians to act on pharmacogenomics findings
50:02 - Advice to junior scientists considering a GPCR or computational career
52:44 - Eureka moment - first hits from 218 peptides screened against orphan receptors

Selected Quotes

"I'm trying to stay in the GPCR field while trying to bring in new methods from other fields and expanding on the clinical implementation and investigation as much as possible."

"It's not enough to just be able to manipulate datasets. You really need to also combine it with domain knowledge. Otherwise it's just numbers and labels - and it becomes very quickly very meaningless."

"It's important to have clinicians on board very early on. Because otherwise you just throw another paper out there, but it doesn't get traction - it stays in the community. If your ambition is that it has an impact on the patient, then you have to work with the people who are eventually using that information."

"Every new result leads you to be more hopeful or to be happier about the outcome. In science you always have to be skeptical about your results. So every time you have your results, you're less skeptical - and that can make you happy."

About Dr. Alexander S. Hauser

Alexander is currently a postdoc as a member of the personalized medicine cluster in Copenhagen and at the Institute of Biological Psychiatry in Roskilde working with the UK Biobank and other large-scale population cohorts.

Alexander has a big interest in the integration of large biomedical data in genomics, structural biology, pharmacology, and pharmacoepidemiology with innovative computational methods to gain novel insights into receptor biology.

During his Ph.D. with David Gloriam at the Department of Drug Design and Pharmacology in Copenhagen, he worked on novel analytical methods to identify human signaling systems and thereby discovered endogenous peptides activating several orphan receptors. Alexander had a research sabbatical with Madan Babu at the MRC Laboratory of Molecular Biology in Cambridge, UK, where he was working on the impact of genetic variations on drug response. He received the “HC Ørsted Research talent prize” and “Bayer Pharmaceuticals Ph.D. Award” for his work on GPCRs.

Dr. Alexander S. Hauser on the web